ALKIXEN 250 mg (Crizotinib): Uses, Dosage, Side Effects & Safety
ALKIXEN 250 mg (Crizotinib): Uses, Dosage, Side Effects & Safety
What Is ALKIXEN 250 mg?
ALKIXEN 250 mg contains Crizotinib, an oral targeted anticancer medicine belonging to the kinase inhibitor class.
Crizotinib is used in specific patients whose cancer contains certain molecular abnormalities. In adult patients, regulatory information includes treatment of metastatic non-small cell lung cancer (NSCLC) with ALK-positive or ROS1-positive tumours when the relevant biomarker has been confirmed by an appropriate approved test.
Crizotinib is also approved in the United States for certain patients with ALK-positive inflammatory myofibroblastic tumour and for pediatric patients and young adults with ALK-positive systemic anaplastic large cell lymphoma in specified settings.
ALKIXEN 250 mg is supplied as a capsule containing 250 mg of Crizotinib. The stated product pack size is 60 capsules.
Because Crizotinib is a prescription anticancer medicine, treatment should be selected and supervised by an appropriately qualified oncology professional.
What Is Crizotinib?
Crizotinib is a molecularly targeted medicine that inhibits several receptor tyrosine kinases involved in cancer-cell signalling.
Its best-known therapeutic targets include:
- Anaplastic lymphoma kinase (ALK)
- ROS1
- MET
Some cancers contain genetic rearrangements or alterations that lead to abnormal signalling through these proteins. Such signalling can contribute to tumour-cell growth, survival and progression.
Crizotinib works by inhibiting kinase activity associated with these molecular targets.
This makes Crizotinib different from conventional chemotherapy. Instead of broadly targeting rapidly dividing cells, it is designed to interfere with specific molecular pathways that may be driving a patient's cancer.
What Is Crizotinib Used For?
Crizotinib is used for selected cancers with appropriate molecular characteristics.
ALK-Positive Non-Small Cell Lung Cancer
Crizotinib is indicated for patients with metastatic NSCLC whose tumours are confirmed to be ALK-positive using an appropriate approved diagnostic test.
ALK-positive NSCLC represents a molecularly defined subgroup of lung cancer in which abnormal ALK signalling contributes to tumour biology.
ROS1-Positive Non-Small Cell Lung Cancer
Crizotinib is also used for metastatic NSCLC with ROS1-positive tumours in applicable regulatory settings.
ALK-Positive Inflammatory Myofibroblastic Tumour
U.S. regulatory information includes Crizotinib for adults and pediatric patients aged 1 year and older with unresectable, recurrent or refractory ALK-positive inflammatory myofibroblastic tumour.
ALK-Positive Anaplastic Large Cell Lymphoma
Crizotinib has a U.S. indication for pediatric patients aged 1 year and older and young adults with relapsed or refractory systemic ALK-positive anaplastic large cell lymphoma.
Approved uses can differ between countries, so the applicable local prescribing information should always be consulted.
Key Indications
ALK-Positive NSCLC
Patient-friendly explanation:
Crizotinib may be used when a lung cancer tumour has an ALK alteration that makes the cancer susceptible to ALK-targeted treatment.
Medical explanation:
Crizotinib inhibits ALK kinase activity and interferes with signalling pathways involved in proliferation and survival of ALK-dependent tumour cells.
ROS1-Positive NSCLC
Patient-friendly explanation:
Some lung cancers are driven by abnormal ROS1 signalling. Crizotinib can target ROS1 in eligible patients.
Medical explanation:
Crizotinib inhibits ROS1 kinase activity and suppresses ROS1-dependent signalling.
ALK-Positive Rare Tumours
Crizotinib has additional regulatory indications in selected patients with ALK-positive inflammatory myofibroblastic tumour and systemic anaplastic large cell lymphoma.
How Does Crizotinib Work?
Crizotinib works by inhibiting receptor tyrosine kinases involved in cancer signalling.
The most clinically important targets are ALK and ROS1, with additional activity against MET.
Normally, receptor tyrosine kinases participate in cellular communication. They receive signals and activate intracellular pathways that influence:
- Cell proliferation
- Cell survival
- Cell migration
- Cellular differentiation
- Tissue growth
In some cancers, genetic rearrangements or other molecular changes can cause these signalling proteins to remain abnormally active.
The simplified process can be represented as:
ALK/ROS1 alteration → abnormal kinase signalling → downstream signalling → cancer-cell growth and survival
Crizotinib interferes with this process:
Crizotinib → kinase inhibition → reduced abnormal signalling → reduced growth/survival signalling
The medicine therefore acts as a targeted molecular inhibitor rather than as a nonspecific cytotoxic agent.
The clinical benefit depends on whether the patient's tumour contains a molecular target that Crizotinib can effectively inhibit.
For this reason, biomarker testing is an important component of selecting appropriate patients for targeted therapy.
Crizotinib 250 mg Dosage and Administration
For the FDA-approved adult NSCLC indication, the recommended dose is:
250 mg orally twice daily.
This corresponds to a total daily dose of 500 mg.
Administration Instructions
- Take Crizotinib exactly as prescribed.
- The standard adult regimen is taken approximately twice daily.
- Crizotinib may be taken with or without food.
- Swallow capsules whole.
- Do not crush, chew or alter capsules unless specifically instructed by a healthcare professional.
- Continue treatment according to the oncology treatment plan.
- Do not change the dose without medical advice.
Dose Adjustments
Dose reduction or treatment interruption may be required for certain adverse reactions or organ-function abnormalities.
FDA labeling describes stepwise dose reductions from 250 mg twice daily to 200 mg twice daily and then 250 mg once daily when clinically necessary.
Patients with certain degrees of hepatic or renal impairment may require modified dosing.
Missed Dose
If a dose is missed, the FDA label advises taking the missed dose unless the next scheduled dose is due within 6 hours.
Patients should not take extra doses unless specifically instructed.
Vomiting After a Dose
If vomiting occurs after taking Crizotinib, the next dose should generally be taken at the regular scheduled time rather than automatically repeating the dose.
Crizotinib Side Effects
Crizotinib can cause adverse effects, and individual responses vary.
Common Side Effects
Reported adverse reactions include:
- Visual disturbances
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Oedema
- Fatigue
- Increased liver enzymes
- Decreased appetite
These effects were among the commonly reported adverse reactions in clinical experience with Crizotinib.
Less Common Side Effects
Other clinically relevant effects may include:
- Dizziness
- Peripheral neuropathy
- Reduced blood-cell counts
- Kidney function changes
- Electrolyte abnormalities
- Heart-rate changes
- Liver abnormalities
Serious Side Effects
Important serious risks include:
- Hepatotoxicity
- Interstitial lung disease or pneumonitis
- QT-interval prolongation
- Severe bradycardia
- Serious visual or neurological symptoms
- Severe allergic reactions
FDA sources identify hepatotoxicity, interstitial lung disease/pneumonitis and QT prolongation among important serious toxicities associated with Crizotinib.
When to Seek Medical Attention
Prompt medical attention is appropriate if a patient experiences:
- New or worsening difficulty breathing
- Persistent cough
- Chest pain
- Fainting
- Significant palpitations
- Severe dizziness
- Yellowing of the skin or eyes
- Severe abdominal symptoms
- Unusual bleeding
- Severe allergic symptoms
Crizotinib Drug Interactions
Crizotinib can interact with other medicines by altering drug metabolism or increasing the risk of certain adverse effects.
Medicines Requiring Monitoring
Particular attention may be required with:
- CYP3A inhibitors
- CYP3A inducers
- Medicines that prolong the QT interval
- Medicines that reduce heart rate
- Certain hepatotoxic medicines
Patients should provide their healthcare professional with a complete medication list before starting treatment.
Heart-Rhythm Medicines
Because Crizotinib can affect cardiac repolarization and prolong the QT interval, combinations with other QT-prolonging medicines may require particular caution.
Food Considerations
Crizotinib may be taken with or without food according to FDA prescribing information.
Patients should follow the instructions accompanying their specific product.
Supplement Considerations
Patients should discuss the use of:
- Herbal medicines
- St John's wort
- Traditional medicines
- High-dose supplements
- Unregulated cancer products
with their healthcare provider before using them during treatment.
Warnings and Precautions
Liver Considerations
Crizotinib can cause liver toxicity and increased liver enzymes.
Liver-function testing may therefore be required during treatment.
Symptoms such as:
- Yellow skin or eyes
- Dark urine
- Severe fatigue
- Abdominal discomfort
should be reported promptly.
Lung Considerations
Interstitial lung disease or pneumonitis is a potentially serious adverse reaction.
New or worsening respiratory symptoms should receive prompt medical evaluation.
Cardiovascular Considerations
Crizotinib can cause QT-interval prolongation and, in some patients, bradycardia.
Patients with pre-existing cardiac conditions or those taking medicines affecting cardiac rhythm should inform their physician.
Vision Considerations
Visual disturbances are among the recognized adverse reactions associated with Crizotinib.
Patients should report persistent or severe changes in vision.
Kidney Considerations
Kidney function may require monitoring, particularly in patients with pre-existing renal impairment.
Special Monitoring Requirements
Depending on the patient's condition, monitoring may include:
- Liver function tests
- Kidney function
- Complete blood counts
- Electrolytes
- Heart rhythm
- ECG when clinically appropriate
- Visual symptoms
- Respiratory symptoms
Pregnancy and Breastfeeding
Crizotinib may cause fetal harm based on its pharmacological properties and available nonclinical information.
Women who may become pregnant should discuss effective contraception with their healthcare professional before and during treatment.
Pregnancy should be discussed promptly with the treating physician if it occurs during treatment.
Breastfeeding should be discussed with the treating healthcare provider. Patients should follow the current product-specific prescribing information regarding breastfeeding and treatment.
Special Populations
Elderly Patients
Older adults may receive Crizotinib when clinically appropriate, but treatment should consider:
- General health
- Other medications
- Liver function
- Kidney function
- Cardiovascular status
- Risk of drug interactions
Pediatric Patients
Crizotinib has specific pediatric indications in certain ALK-positive malignancies. Pediatric dosing is not automatically the same as adult dosing and should be determined by a specialist according to the applicable indication and prescribing information.
Renal Impairment
Patients with severe renal impairment may require a modified regimen.
FDA prescribing information specifies a reduced dose for patients with severe renal impairment who are not receiving dialysis.
Hepatic Impairment
Patients with moderate or severe hepatic impairment may require dose adjustment.
The treating physician should assess liver function before and during treatment where appropriate.
Storage of ALKIXEN 250 mg
Store ALKIXEN according to the product packaging and official product-specific storage instructions.
General precautions include:
- Keep capsules in their original packaging.
- Protect the medicine from excessive heat and moisture.
- Keep out of reach of children.
- Do not use damaged or visibly altered capsules.
- Follow the storage temperature stated on the product label.
Frequently Asked Questions About ALKIXEN 250 mg
1. What is ALKIXEN 250 mg used for?
ALKIXEN 250 mg contains Crizotinib, a targeted medicine used for selected cancers with specific molecular abnormalities, including ALK-positive or ROS1-positive NSCLC in approved settings.
2. What is Crizotinib?
Crizotinib is an oral kinase inhibitor that targets proteins including ALK and ROS1.
3. Is Crizotinib a chemotherapy drug?
Crizotinib is generally classified as a targeted therapy rather than conventional cytotoxic chemotherapy.
4. How does Crizotinib work?
Crizotinib inhibits specific kinase proteins involved in abnormal cancer-cell signalling, particularly ALK and ROS1.
5. What is the usual adult dose of Crizotinib?
For the FDA-approved adult NSCLC indication, the recommended dose is 250 mg twice daily.
6. Can Crizotinib be taken with food?
Yes. FDA prescribing information states that Crizotinib may be taken with or without food.
7. What are common Crizotinib side effects?
Common adverse effects include visual disturbances, nausea, diarrhea, vomiting, constipation, oedema, fatigue and elevated liver enzymes.
8. Can Crizotinib affect vision?
Yes. Visual disturbances are a recognized adverse effect of Crizotinib.
9. Can Crizotinib affect the liver?
Yes. Hepatotoxicity and increased liver enzymes can occur, so liver monitoring may be required.
10. Can Crizotinib cause lung problems?
Interstitial lung disease and pneumonitis are important potential adverse reactions and require prompt assessment if respiratory symptoms develop.
11. Can Crizotinib affect heart rhythm?
Yes. Crizotinib can prolong the QT interval and may cause bradycardia in some patients.
12. What should I do if I miss a Crizotinib dose?
If a dose is missed, follow the product instructions. FDA labeling advises taking the missed dose unless the next dose is due within 6 hours.
13. Is Crizotinib used for ALK-positive lung cancer?
Yes. Crizotinib is an approved targeted treatment for selected patients with ALK-positive metastatic NSCLC.
14. Is Crizotinib used for ROS1-positive lung cancer?
Yes. It is used for selected patients with metastatic ROS1-positive NSCLC in applicable regulatory settings.
15. Can Crizotinib treat other cancers?
Crizotinib also has specific regulatory indications for certain ALK-positive inflammatory myofibroblastic tumours and ALK-positive systemic anaplastic large cell lymphoma.
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides pharmaceutical information and specialty-medicine support for individuals and organizations seeking information about prescription and high-value medicines.
Our educational resources cover:
- Oncology medicines
- Hematology treatments
- Targeted cancer therapies
- Generic medicines
- Medicine uses and indications
- Dosage information
- Safety considerations
- Drug interactions
- International medicine information
- Prescription-related support
For targeted oncology medicines such as Crizotinib, patients should obtain appropriate medical evaluation and confirm molecular testing before treatment.
RootAid Pharma can provide medicine-related information and supply assistance where legally and operationally applicable. Availability, prescription requirements, import regulations and medicine-supply conditions may vary between countries.
RootAid Pharma does not replace a physician, oncologist or pharmacist and does not claim to manufacture ALKIXEN or Crizotinib.
Medical Disclaimer
This article is intended for general educational and informational purposes only. It is not a substitute for medical diagnosis, individualized treatment planning, prescribing information or advice from a qualified physician, oncologist, pharmacist or other licensed healthcare professional.
Crizotinib is a prescription anticancer medicine intended for patients who meet specific clinical and molecular criteria. The correct dose, treatment duration, dose modifications, monitoring and suitability must be determined by the treating healthcare professional.
Approved indications, formulations, dosing recommendations and regulatory requirements can vary between countries and may change over time. Patients and healthcare professionals should consult the official product information applicable to their country.
Do not start, stop, increase or reduce Crizotinib without professional medical advice.
Medical verification: The clinical sections above were checked against FDA prescribing information and FDA regulatory records for Crizotinib.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.